Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma

Table 4 Late adverse events in the two groups n (%)

Late adverse event	NDP group	DDP group	χ2	P value
Late esophageal injury
0	18 (52.9)	13 (38.2)
I	10 (29.4)	12 (35.3)
II	4 (11.8)	5 (14.7)	2.299	0.681
III	2 (5.9)	3 (8.8)
IV	0 (0)	1 (2.9)
Late lung injury
0	24 (70.6)	20 (58.8)
I	7 (20.6)	8 (23.5)
II	2 (5.9)	4 (11.8)	1.43	0.698
III	1 (2.9)	2 (5.9)
IV	0 (0)	0 (0)

NDP: Nedaplatin; DDP: Cisplatin.